Pharmacokinetics of aminoguanidine administration and effects on the diabetes frequency in nonobese diabetic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 790-794

  Bowman, Mark A ^a   Simell, Olli G ^b   Peck, Ammon B ^a   Cornelius, Janet ^a   Luchetta, Roberto ^a   Look, Zee ^c   Maclaren, Noel K ^a   Atkinson, Mark A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c Alteon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CELL DESTRUCTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; FEMALE; GUANIDINES; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 0030426711     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ATKINSON, M. A. AND MACLAREN, N. K.: The pathogenesis of insulin-dependent diabetes mellitus. N. Engl. J. Med. 331: 1428-1436, 1994.
2. BOWMAN, M. A., CAMPBELL, L., DARROW, B. L., ELLIS, T. M., SURESH, A. AND ATKINSON, M. A.: Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45: 205-208, 1996.
3. BOWMAN, M. A., LEITER, E. H. AND ATKINSON, M. A.: Prevention of diabetes in the NOD mouse: Implications for therapeutic intervention in human disease. Immunol. Today 15: 115-120, 1994.
4. BROWNLEE, M. H., VLASSARA, H., KOONEY, A., ULRICH, P. AND CERAMI A.: Amino-guanidine prevents diabetes induced arterial wall protein cross-linking. Science 240: 1629-1632, 1986.
5. CASTANO, L. AND EISENBARTH, G. S.: Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol. 8: 647-679, 1990.
6. CORBETT, J. A. AND MCDANIEL, M. L.: Does nitric oxide mediate autoimmune destruction of beta cells? Possible therapeutic interventions in IDDM. Diabetes 41: 897-903, 1992.
7. CORBETT, J. A., MIKHAEL, A., SHIMIZU, J., FREDERICK, K., MISKO, T. P., MCDANIEL, M. L., KANAGAWA, O. AND UNANUE, E. R.: Nitric oxide production in islets from nonobese diabetic mice: Aminoguanidine-sensitive and resistant stages in the immunological diabetic process. Proc. Natl. Acad. Sci. U.S.A. 90: 8992-8995, 1993a.
8. CORBETT, J. A., SWEETLAND, M. A., WANG, J. L., LANCASTER, J. R. AND MCDANIEL, M. L.: Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. U.S.A. 90: 1731-1735, 1993b.
9. CORBETT, J. A., WANG, J. L., SWEETLAND, M. A., LANCASTER, J. R., JR. AND MCDANIEL, M. L.: Interleukin-1-beta induces the formation of nitric oxide by beta cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J. Clin. Invest. 90: 2384-2391, 1992.
10. CROSS, A. H., MISKO, T. P., LIN, R. F., HICKEY, W. F., TROTTER, J. L. AND TILTON, R. G.: Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93: 2684-2690, 1994.
11. DING, A. H., NATHAN, C. F. AND STUEHR, D. J.: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines. J. Immunol. 141: 2407-2412, 1988.
12. DRAPIER, J. C. AND HIBBS, J. B.: Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial ironsulfur enzymes in the macrophage effector cell. J. Immunol. 140: 2829-2838, 1988.
13. DRAPIER, J. C., WIETZERBIEN, J. AND HIBBS, J. B.: Interferon gamma and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol. 18: 1587-1592, 1988.
14. EIZIRIK, D. L., SANDLER, S., WELSH, N., CETKOVIC-CVRLJE, M., NIEMAN, A., GELLER, D. A., PIPELEERS, D. G., BENDTZEN, K. AND HELLERSTROM, C.: Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest. 93: 1968-1974, 1994.
15. ELLIS, E. N. AND GOOD, B. H.: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40: 1016-1019, 1991.
16. ELLMAN, C., CORBETT, J. A., MISKO, T. P., MCDANIEL, M. AND BECKERMAN, K. P.: Nitric oxide mediates interleukin-1-induced cellular cytotoxicity in the rat ovary. A potential role for nitric oxide in the ovulatory process. J. Clin. Invest. 92: 3053-3056, 1993.
17. FEHSEL, K., JALOWY, A., QI, S., BURKART, V., HARTMANN, B. AND KOLB, H.: Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes 42: 496-500, 1993.
18. HAMMES, H. P., MARTIN, S., FEDERLIN, K, GEISEN, K. AND BROWNLEE, M.: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U.S.A. 88: 11555-11558, 1991.
19. + islet-specific T cell clone. Science 249: 1433-1436, 1990.
20. HASKINS, K., PORTAS, M., BRADLEY, B., WEGMANN, D. AND LAFFERTY, K.: T-lymphocyte clone specific for pancreatic islet antigen. Diabetes 37: 1444-1448, 1988.
21. HENRY, Y., DUCROCQ, C., DRAPIER, J. C., SERVENT, D., PELLAT, C. AND GUISANI, A.: Nitric oxide, a biologic effector. Electron paramagnetic resonance detection of nitrosyl-iron-protein complexes in whole cells. Eur. Biophys. J. 20: 1-15, 1991.
22. JARPE, A. J., HICKMAN, M., ANDERSON, J. T., WINTER, W. E. AND PECK, A. B.: Flow cytometric enumeration of mononuclear cell populations infiltrating the islets of Langerhans in prediabetic NOD mice: development of a model of autoimmune insulitis for type I diabetes. Regional Immunol. 3: 305-317, 1991.
23. KOLB, H. AND BACHOFEN, V. K.: Nitric oxide: A pathogenic factor in autoimmunity. Immunol. Today 13: 157-160, 1992.
24. LARGER, E., BECOURT, C., BACH, J. F., BOITARD, C.: Pancreatic islet β cells drive T cell-immune responses in the nonobese diabetic mouse model. J. Exp. Med. 181: 1635-1642, 1995.
25. LEE, K. U., AMANO, K. AND YOON, J. W.: Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 37: 989-991, 1988.
26. LEITER, E. H.: The NOD mouse: A model for analyzing the interplay between heredity and environment in the development of autoimmune disease. ILAR News 35: 4-14, 1993.
27. LIEW, F. Y. AND COX, F. E. G.: Non-specific defense mechanism: The role of nitric oxide. Immunol. Today 12: 17-21, 1991.
28. LIN, R. F., LIN, T. T., TILTON, R. G. AND CROSS, A. H.: Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: An electron paramagnetic study. J. Exp. Med. 178: 643-648, 1993.
29. MISKO, T. P., MOORE, W. M., KASTEN, T. P., NICKOLS, G. A., CORBETT, J. A., TILTON, R. G., MCDANIEL, M. L., WILLIAMSON, J. R. AND CURRIE, M. G.: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 233: 119-125, 1993.
30. NATHAN, C.: Nitric oxide as a secretory product of mammalian cells. FASEB J. 6: 3051-3064, 1992.
31. PICARD, S., PATHASARATHY, S., FRUEBIS, J. AND WITZUM, J. L.: Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc. Natl. Acad. Sci. U.S.A. 89: 6876-6880, 1992.
32. RABINOVITCH, A., SUAREZ-PINZON, W. L., SHI, Y., MORGAN, A. R. AND BLEACKLEY, R. C.: DNA fragmentation is an early event in cytokine-induced islet beta-cell destruction. Diabetologia 37: 733-738, 1994a.
33. RABINOVITCH, A., SUAREZ-PINZON, W. L., STRYNADKA, K., SCHULZ, R., LAKEY, J. R. T., WARNOCK, G. L. AND RAJOTTE, R. V.: Human pancreatic islet beta cell destruction by cytokines is independent of nitric oxide production. J. Clin. Endocrinol. Metab. 79: 1-5, 1994b.
34. RADONS, J., HELLER, B., BURKLE, A., HARTMANN, B., RODRIGUEZ, M. L., KRONCKE, K. D., BURKART, V. AND KOLB, H.: Nitric oxide toxicity in islet cells involves poly (ADP-ribose) polymerase activation and concomitant NAD+ depletion. Biochem. Biophys. Res. Commun. 199: 1270-1277, 1993.
35. RAPOPORT, M. J., JARAMILLO, A., ZIPRIS, D., LAZARUS, A. H., SERREZE, D. V., LEITER, E. H., CYOPICK, P., DANSKA, J. S. AND DELOVITCH, T. L.: Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178: 87-99, 1993.
36. SERREZE, D. V., HAMAGUCHI, K. AND LEITER, E. H.: Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun, 2: 759-776, 1990.
37. TISCH, R. AND MCDEVITT, H.: Insulin-dependent diabetes mellitus. Cell 85: 291-297, 1996.
38. SHIZURU, J. A., TAYLOR-EDWARDS, C., BANKS, B. A., GREGORY, A. K. AND FATHMAN, C. G.: Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 240: 659-662, 1988.
39. STUEHR, D. J., CHO, H. J., KWON, N. S., WEISE, M. F. AND NATHAN, C. F.: Purification and characterization of the cytokine-induced macrophage nitric oxide synthase. An FAD- and FMN-containing flavoprotein. Proc. Natl. Acad. Sci. U.S.A. 88: 7773-7777, 1991.
40. WANG, Y., HAO, L., GILL, R. G. AND LAFFERTY, K J.: Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 36: 535-538, 1987.
41. + T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 88: 527-531, 1991.
42. WICKER, L. S., MILLER, B. J., COKER, L. Z., MCNALLY, S. E., SCOTT, S., MULLEN, Y. AND APPEL, M. C.: Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse. J. Exp. Med. 165: 1639-1654, 1987.
43. XIE, Q. W., CHO, H. J., CALAYCAY, J., MUMFORD, R. A., SWIDERED, K. M., LEE, T. D., DING, A., TROSO, T. AND NATHAN, C.: Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256: 225-228, 1992.